JP2019537424A5 - - Google Patents

Download PDF

Info

Publication number
JP2019537424A5
JP2019537424A5 JP2019512267A JP2019512267A JP2019537424A5 JP 2019537424 A5 JP2019537424 A5 JP 2019537424A5 JP 2019512267 A JP2019512267 A JP 2019512267A JP 2019512267 A JP2019512267 A JP 2019512267A JP 2019537424 A5 JP2019537424 A5 JP 2019537424A5
Authority
JP
Japan
Prior art keywords
amino acid
protein
recombinant protein
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019512267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537424A (ja
JP7183149B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/049894 external-priority patent/WO2018045308A1/en
Publication of JP2019537424A publication Critical patent/JP2019537424A/ja
Publication of JP2019537424A5 publication Critical patent/JP2019537424A5/ja
Priority to JP2022186724A priority Critical patent/JP7500692B2/ja
Application granted granted Critical
Publication of JP7183149B2 publication Critical patent/JP7183149B2/ja
Priority to JP2024091170A priority patent/JP2024123036A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019512267A 2016-09-02 2017-09-01 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用 Active JP7183149B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022186724A JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2024091170A JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383267P 2016-09-02 2016-09-02
US62/383,267 2016-09-02
PCT/US2017/049894 WO2018045308A1 (en) 2016-09-02 2017-09-01 Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022186724A Division JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用

Publications (3)

Publication Number Publication Date
JP2019537424A JP2019537424A (ja) 2019-12-26
JP2019537424A5 true JP2019537424A5 (enExample) 2020-09-17
JP7183149B2 JP7183149B2 (ja) 2022-12-05

Family

ID=59887401

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019512267A Active JP7183149B2 (ja) 2016-09-02 2017-09-01 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2022186724A Active JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2024091170A Pending JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022186724A Active JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2024091170A Pending JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用

Country Status (11)

Country Link
US (3) US11338033B2 (enExample)
EP (1) EP3506938A1 (enExample)
JP (3) JP7183149B2 (enExample)
KR (2) KR20190056382A (enExample)
CN (2) CN110167585B (enExample)
AU (2) AU2017321883B2 (enExample)
BR (1) BR112019004189A2 (enExample)
CA (1) CA3035443A1 (enExample)
IL (3) IL303650B2 (enExample)
SG (2) SG11201901790YA (enExample)
WO (1) WO2018045308A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3906939A1 (en) 2013-10-11 2021-11-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
KR20190056382A (ko) * 2016-09-02 2019-05-24 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
GB2578163A (en) * 2018-10-19 2020-04-22 Univ Pretoria Plant produced avian influenza antigens and their uses in diagnostic assays and devices
US12433943B2 (en) 2019-02-08 2025-10-07 University Of Washington Nanoparticle-based influenza virus vaccines and uses thereof
WO2021174132A2 (en) * 2020-02-26 2021-09-02 The Wistar Institute Of Anatomy & Biology Compositions comprising self-assembling vaccines and methods of using the same
CN111560074B (zh) * 2020-03-20 2021-07-09 中山大学 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
MX2023011400A (es) 2021-03-26 2023-10-09 Glaxosmithkline Biologicals Sa Composiciones inmunogenicas.
US20240165224A1 (en) 2021-03-26 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP4362974A1 (en) 2021-06-28 2024-05-08 GlaxoSmithKline Biologicals S.A. Novel influenza antigens
AU2022345984A1 (en) 2021-09-16 2024-04-04 Emergent Product Development Gaithersburg Inc. Vaccine compositions
WO2023061993A1 (en) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
CN115850396B (zh) * 2022-12-22 2024-02-06 北京吉诺卫生物科技有限公司 一种rsv纳米颗粒疫苗及其制备方法与应用
WO2024131862A1 (zh) * 2022-12-22 2024-06-27 北京吉诺卫生物科技有限公司 一种rsv疫苗及其制备方法与应用
WO2024163912A2 (en) * 2023-02-03 2024-08-08 The Children's Medical Center Corporation Vaccine and therapeutic protein delivery compositions comprising fusion proteins
WO2024167855A1 (en) 2023-02-06 2024-08-15 Emergent Product Development Gaithersburg Inc. Influenza hemagglutinin constructs and compositions
WO2024197134A1 (en) * 2023-03-21 2024-09-26 President And Fellows Of Harvard College Coronavirus spike protein-based vaccines

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
CA2462455C (en) 2001-10-01 2012-07-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
US7097841B2 (en) 2002-05-10 2006-08-29 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
JP4726483B2 (ja) 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー 分子抗原アレイ
US20060130158A1 (en) 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
GB0319797D0 (en) 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US7897408B2 (en) 2005-09-12 2011-03-01 Japan Science And Technology Agency Method for producing CdS-apoferritin and ZnS-apoferritin complexes
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
WO2008087563A2 (en) 2006-12-29 2008-07-24 Institut Pasteur Of Shanghai Lentivirus pseudotyped with influenza hemagglutinin and methods of use
WO2008145129A2 (en) 2007-05-31 2008-12-04 Statens Serum Institut Influenza vaccines
US8778847B2 (en) 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
CA2696764A1 (en) 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
WO2009109428A2 (en) 2008-02-01 2009-09-11 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
JP5382489B2 (ja) 2008-03-29 2014-01-08 国立大学法人 奈良先端科学技術大学院大学 円偏光発光性ナノ微粒子
US20110177122A1 (en) 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
JP2012521786A (ja) * 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
SG178918A1 (en) 2009-09-22 2012-04-27 Medicago Inc Method of preparing plant-derived vlps
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
CA2789945A1 (en) 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
EP2652496B1 (en) * 2010-12-13 2018-01-17 The University of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
HK1200102A1 (en) 2011-09-20 2015-07-31 西奈山医学院 Influenza virus vaccines and uses thereof
WO2013044203A2 (en) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
AU2012343981B2 (en) 2011-11-28 2017-09-07 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2013177444A2 (en) 2012-05-23 2013-11-28 The Board Of Trustees Of The Leland Stanford Junior University Influenza vaccine constructs
NZ627796A (en) 2012-12-18 2017-07-28 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
CA2913859C (en) * 2013-05-30 2021-11-30 Crucell Holland B.V. Influenza virus vaccines and uses thereof
EP3906939A1 (en) 2013-10-11 2021-11-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
CN111500631B (zh) 2013-10-28 2024-03-29 蓝天免疫疗法有限责任公司 用于病毒疗法的新型流感病毒载体
PT3148578T (pt) * 2014-05-27 2022-08-23 Us Health Trímeros estabilizados da região do caule da hemaglutinina do vírus da gripe e suas utilizações
SG11201610456UA (en) 2014-07-10 2017-01-27 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
CN106795513B (zh) 2014-08-08 2021-06-11 Vlp治疗公司 包含修饰的包膜蛋白e3的病毒样颗粒
KR102713707B1 (ko) 2014-12-31 2024-10-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 신규 다가 나노입자 기반 백신
WO2018005558A1 (en) 2016-06-27 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
KR20190056382A (ko) * 2016-09-02 2019-05-24 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
WO2021231729A1 (en) * 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza

Similar Documents

Publication Publication Date Title
JP2023018073A5 (enExample)
US12527857B2 (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
US12433943B2 (en) Nanoparticle-based influenza virus vaccines and uses thereof
TWI874544B (zh) 變異型rsv f蛋白質及其利用
CN107488218B (zh) 一种多肽、免疫原性偶联物和流感疫苗
KR102777000B1 (ko) 인플루엔자 바이러스 백신 및 이의 용도
WO2012163289A1 (zh) 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
CN105452270A (zh) 流行性感冒病毒疫苗及其用途
JP2015509707A5 (enExample)
JP2018531578A5 (enExample)
US20160000901A1 (en) Compositions and Methods for the Production of Virus-Like Particles
CN107344969A (zh) 一种纳米流感疫苗及构建方法和应用
JP7545955B2 (ja) インフルエンザhaスプリットワクチンの製造方法
Lim et al. RNA-dependent assembly of chimeric antigen nanoparticles as an efficient H5N1 pre-pandemic vaccine platform
Sheng et al. Apoferritin nanoparticle based dual-antigen influenza conjugate vaccine with potential cross-protective efficacy against heterosubtypic influenza virus
WO2018175560A1 (en) Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
WO2020246584A1 (ja) ペプチド核酸を基盤としたアジュバント
Zhu et al. Protection against the H1N1 influenza virus using self-assembled nanoparticles formed by lumazine synthase and bearing the M2e peptide
CN110201183A (zh) 一种可同时递送抗原和免疫增强剂的纳米制剂
Kotlyarov et al. Development of recombinant vaccine against A (H1N1) 2009 influenza based on virus-like nanoparticles carrying the extracellular domain of M2 protein
CN106337038B (zh) 一种通过转肽酶剪切制备疫苗的方法及其应用
CN103242426B (zh) 禽流感病毒h5n1亚型限制性ctl表位多肽及其应用
WO2024199469A1 (zh) 具有稳定融合前构象的呼吸道合胞病毒f蛋白